This move is archived. Current quotes and coverage live on the stock page.
Get BCT alerts:
Briacell Therapeutics Corp (BCT.TO) has seen a remarkable surge in its stock price, closing up 7.11% in the latest trading session.
In a notable performance on the TSX, Briacell Therapeutics Corp's stock has jumped to CA$5.27, reflecting a strong investor response to recent strategic developments. The company, which specializes in immunotherapies for cancer treatment, is positioning itself for potential market opportunities that could reshape its future.
Advertisement
Briacell Therapeutics Corp
BCT.TO
BCT.TO
Briacell Therapeutics Corp
WealthAwesomeMarket cap
$43.32M
52W high
$20.40
52W low
$3.68
1W change
-1.39%
Beta
1.53
Analyst Price Targets
Based on analyst covering BCT · as of Sep 17, 2026
Wall Street analysts forecast BCT stock price to rise 301.6% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$20.00
+301.6% Upside
Current Price
C$4.98
Last close
Targets are snapshotted when they change. Unchanged figures keep their original date. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on BCT's historical volatility
30-Day Vol
91.8%
Annualized
90-Day Vol
91.9%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$7.08
Expected price
| Horizon | Expected | 68% Range (1σ) |
|---|---|---|
| 30 trading days | C$6.28 | C$4.58 – C$8.62 |
| 60 trading days | C$6.67 | C$4.26 – C$10.44 |
| 90 trading days | C$7.08 | C$4.09 – C$12.25 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ±1σ, 95% band = ±2σ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Investors are optimistic about Briacell's recent engagement with consulting firms to enhance its commercial strategy, which could pave the way for future growth in the competitive biotech sector.
Briacell Therapeutics Corp's stock rises by 7.11%
This increase brings the company's market cap to approximately CA$42.8 million, underscoring the impact of strategic planning on investor sentiment.
Bull case
The partnership with Charles River Associates and Kaleio, Inc. shows that Briacell is taking a proactive approach to market access and brand strategy. This could lead to successful commercialization of Bria-IMT, which is currently in pivotal Phase 3 trials.
Bear case
Despite the positive momentum, the company still lacks current revenue, and the risks associated with clinical trials mean that investors should be cautious about the stock's long-term viability.
Advertisement
Strategic Partnerships Fuel Growth
Briacell's recent collaboration with Charles River Associates and Kaleio, Inc. is a crucial step in evaluating the commercial potential of its lead product, Bria-IMT. This partnership aims to assess market access strategies and pricing dynamics, which could significantly enhance the company's positioning in the competitive oncology market.
Market Reaction and Future Prospects
The stock's impressive rise reflects strong investor confidence in Briacell's strategic direction. As the company continues its pivotal Phase 3 study, the anticipation surrounding potential regulatory approvals and market entry for Bria-IMT is likely to keep investor interest high. However, the path to commercialization remains fraught with uncertainty, necessitating a balanced view.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile →✅ Reviewed by Certified Financial Professionals
This content has been reviewed by CFA® charterholders and Certified Financial Planners (CFP®) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFA® charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFP® professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
⚠️ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
